CN116710135A - 用于治疗眼部疾病的方法和试剂 - Google Patents
用于治疗眼部疾病的方法和试剂 Download PDFInfo
- Publication number
- CN116710135A CN116710135A CN202180082106.9A CN202180082106A CN116710135A CN 116710135 A CN116710135 A CN 116710135A CN 202180082106 A CN202180082106 A CN 202180082106A CN 116710135 A CN116710135 A CN 116710135A
- Authority
- CN
- China
- Prior art keywords
- antibody
- sequence
- seq
- cdr
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903624A AU2020903624A0 (en) | 2020-10-07 | Methods and agents for the treatment of ocular disease | |
| AU2020903624 | 2020-10-07 | ||
| PCT/AU2021/051173 WO2022073072A1 (en) | 2020-10-07 | 2021-10-07 | Methods and agents for the treatment of ocular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116710135A true CN116710135A (zh) | 2023-09-05 |
Family
ID=81127099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180082106.9A Pending CN116710135A (zh) | 2020-10-07 | 2021-10-07 | 用于治疗眼部疾病的方法和试剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11618782B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4225796A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545579A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230086713A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116710135A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021356298A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301762A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022073072A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| WO2022073072A1 (en) | 2020-10-07 | 2022-04-14 | Implicit Bioscience Limited | Methods and agents for the treatment of ocular disease |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN119859186A (zh) * | 2023-10-20 | 2025-04-22 | 清华大学 | 针对人源piezo2的单克隆抗体及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008515999A (ja) * | 2004-10-12 | 2008-05-15 | ジェネンテック・インコーポレーテッド | 補体関連障害の予防および処置のためのCRIgポリペプチド |
| WO2012138880A2 (en) * | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| WO2015110556A1 (en) * | 2014-01-22 | 2015-07-30 | Université Pierre Et Marie Curie - Paris 6 (Upmc) | Agents for use in the treatment of retinal inflammation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| EP1336620A4 (en) | 2000-11-22 | 2004-11-17 | Mochida Pharm Co Ltd | MONOCLONAL ANTI-CD14 ANTIBODIES INHIBITING THE CD14 / TLR BINDING |
| WO2006063292A1 (en) * | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
| WO2009002790A2 (en) * | 2007-06-26 | 2008-12-31 | Bausch & Lomb Incorporated | Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| WO2009089401A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
| EP3628324A1 (en) * | 2013-11-05 | 2020-04-01 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
| EP3086809A4 (en) * | 2013-12-24 | 2017-11-29 | NovelMed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| WO2016025313A1 (en) * | 2014-08-11 | 2016-02-18 | Samir Patel | Methods for treating or preventing ophthalmological conditions |
| TW201730211A (zh) * | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| AU2018255489B2 (en) * | 2017-04-21 | 2024-06-13 | Implicit Bioscience Limited | CD 14 antagonist antibodies for treating neurodegenerative diseases |
| KR20190059164A (ko) * | 2017-11-22 | 2019-05-30 | 건국대학교 글로컬산학협력단 | 가용성 cd14의 당뇨황반부종 진단 및 치료 용도 |
| WO2022073072A1 (en) | 2020-10-07 | 2022-04-14 | Implicit Bioscience Limited | Methods and agents for the treatment of ocular disease |
-
2021
- 2021-10-07 WO PCT/AU2021/051173 patent/WO2022073072A1/en not_active Ceased
- 2021-10-07 CN CN202180082106.9A patent/CN116710135A/zh active Pending
- 2021-10-07 EP EP21876765.5A patent/EP4225796A4/en active Pending
- 2021-10-07 KR KR1020237015441A patent/KR20230086713A/ko active Pending
- 2021-10-07 AU AU2021356298A patent/AU2021356298A1/en active Pending
- 2021-10-07 IL IL301762A patent/IL301762A/en unknown
- 2021-10-07 JP JP2023546368A patent/JP2023545579A/ja active Pending
-
2022
- 2022-02-23 US US17/678,861 patent/US11618782B2/en active Active
-
2023
- 2023-01-27 US US18/160,355 patent/US12258390B2/en active Active
-
2025
- 2025-02-21 US US19/060,422 patent/US20250230228A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008515999A (ja) * | 2004-10-12 | 2008-05-15 | ジェネンテック・インコーポレーテッド | 補体関連障害の予防および処置のためのCRIgポリペプチド |
| WO2012138880A2 (en) * | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| WO2015110556A1 (en) * | 2014-01-22 | 2015-07-30 | Université Pierre Et Marie Curie - Paris 6 (Upmc) | Agents for use in the treatment of retinal inflammation |
| US20160340424A1 (en) * | 2014-01-22 | 2016-11-24 | Université Pierre Et Marie Curie - Paris | Agents for use in the treatment of retinal inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220220194A1 (en) | 2022-07-14 |
| EP4225796A4 (en) | 2024-11-13 |
| KR20230086713A (ko) | 2023-06-15 |
| US11618782B2 (en) | 2023-04-04 |
| US20240002489A1 (en) | 2024-01-04 |
| AU2021356298A1 (en) | 2023-05-04 |
| AU2021356298A9 (en) | 2024-04-18 |
| JP2023545579A (ja) | 2023-10-30 |
| WO2022073072A1 (en) | 2022-04-14 |
| US20250230228A1 (en) | 2025-07-17 |
| US12258390B2 (en) | 2025-03-25 |
| IL301762A (en) | 2023-05-01 |
| EP4225796A1 (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12258390B2 (en) | Methods and agents for the treatment of ocular disease | |
| TWI419704B (zh) | 預防及治療與補體相關之眼部病症 | |
| CN113544151B (zh) | 抗il-27抗体及其用途 | |
| JP7760626B2 (ja) | 治療に使用するための抗ソルチリン抗体 | |
| CA3078974A1 (en) | Vegfr-antibody light chain fusion protein | |
| KR20200015477A (ko) | 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 | |
| JP2023520516A (ja) | 抗trem2抗体の使用方法 | |
| JP2018530574A (ja) | 患者の加齢黄斑変性を治療する方法 | |
| JP2023551734A (ja) | 眼の疾患を治療するための組成物及び方法 | |
| KR20230146053A (ko) | 보체 c3 항원 결합 단백질 | |
| US20240101681A1 (en) | Methods of use of anti-sortilin antibodies | |
| US20240132597A1 (en) | Methods of use of anti-sortilin antibodies | |
| KR20250021399A (ko) | 안지오포이에틴-관련 단백질 7-특이적 항체 및 그의 용도 | |
| WO2019074912A1 (en) | ANTI-IL-33 THERAPY FOR ATOPIC DERMATITIS | |
| TW202426494A (zh) | 預測對il-6拮抗劑的反應 | |
| HK40121389A (en) | Predicting response to il-6 antagonists | |
| NZ735964B2 (en) | Antibodies Specific For TGF-Beta | |
| NZ717933A (en) | Antibodies specific for tgf-beta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |